This subset of peripheral CD8+ T cells, expressing conventional activation markers (HLA-DR+CD38+) and proliferation marker (Ki67+), was associated with better response to ICB therapies in a variety of cancer types (53, 143, 144, 162, 172, 192). Here, CD38 is linked to cancer.